BRL-301
PreclinicalCell therapy
BRL-301 is one of 75 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Preclinical.
2
Indications
3
Total Trials
3
Active Trials
74
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
328 competitors in Systemic Lupus Erythematosus
#DrugCompanyPhaseTrials
1Olumiant
Eli LillyPhase 3
Stelara
Johnson & JohnsonPhase 3
Rinvoq
AbbViePhase 3
Gazyva
RochePhase 3
Intrarosa
Alnylam PharmaceuticalsPhase 3
Rayos
RRoxane Laboratories
Phase 3
Depo-Provera
Eli LillyPhase 3
Cellcept
NovartisPhase 3
Imuran
LLegacy Health System
Phase 3
Sotyktu
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BRL-301. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Preclinical[1]
- Company
- BBioray Laboratories